New methods of distributing medicines, involving exclusive deals between manufacturers and wholesalers, could cost the National Health Service hundreds of millions of pounds while reducing standards of service, the Office of Fair Trading said on Tuesday.

The OFT urged the government to change its pricing agreement with drug companies - the Pharmaceutical Price Regulation Scheme - to ensure that costs for the NHS do not rise as a result of new distribution arrangements.